Australia rows back on biosimilar naming; waiting game continues in US
This article was originally published in SRA
Executive Summary
Having been among the first to adopt a distinct naming convention for biosimilars, the Australian Therapeutic Goods Administration has now put its policy on hold while the World Health Organization thrashes out its own guidelines for the naming of biologic and biosimilar products1.